677 / 1068
3Gy/fr 3.5 4 dadapt
54Gy 60 66 EQD2(T)
52Gy 57 63 EQD2(OAR)
12% ? ? G3 GI
ART: room for dose escalation ?
- Potential approach for future
trials aimed to avoid surgery ?
29%* ? ? pCR+cCR
- Potentials in exploring protocols of watchful waiting ? (Appelt 2015, Renehan 2016)
*average rate of pCR from randomized
trials with oxaliplatin: 18%
Appelt 2012